The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
- Journal
- PubMed
In The Last Decade
doi.org/w56623243 →Countries where authors are citing The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
This map shows the geographic impact of The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. more than expected).
Fields of papers citing The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
This network shows the impact of The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells..
About The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
This paper, published in 2001, received 1.2k indexed citations . Written by Teru Hideshima, Paul G. Richardson, D Chauhan, Vito J. Palombella, Peter J. Elliott, Julian Adams and K C Anderson covering the research area of Molecular Biology and Hematology. It is primarily cited by scholars working on Molecular Biology (968 citations), Hematology (629 citations) and Oncology (489 citations). Published in PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/w56623243.